Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China

Figure 4 Kaplan-Meier curves of progression-free survival and overall survival in homologous recombination deficiency/homologous recombination proficient cohort. Survival curves were compared, and P values were determined using a 2-sided log-rank test. A: Progression-free survival (PFS) in all colorectal cancer (CRC) patients stratified by homologous recombination deficiency (HRD) and homologous recombination proficient (HRP) status; B: PFS in microsatellite-stable (MSS) CRC patients who received immune checkpoint inhibitors (ICIs), stratified by HRD and HRP status; C: PFS in MSS CRC patients who did not receive ICIs, stratified by HRD and HRP status; D: Overall survival (OS) in all CRC patients stratified by HRD and HRP status; E: OS in MSS CRC patients who received ICIs, stratified by HRD and HRP status; F: OS in MSS CRC patients who did not receive ICIs, stratified by HRD and HRP status. PFS: Progression-free survival; OS: Overall survival; HRD: Homologous recombination deficiency; HRP: Homologous recombination proficient; CRC: Colorectal cancer; MSS: Microsatellite-stable.